AEOLUS PHARMACEUTICALS

Aeolus Pharmaceuticals develops lead compound, AEOL-10150, as a treatment for the pulmonary and delayed effects of acute radiation exposure.

Aeolus Pharmaceuticals, Inc. is developing its lead compound, AEOL-10150, as a treatment for the pulmonary and delayed effects of acute radiation exposure (“Lung-ARS” and “DEARE”). The Company’s development work is funded under a five year, $118 million, cost-plus contract with the Biomedical Advanced Research and Development Authority (“BARDA”), a division of the U.S. Department of Health and Human Services. BARDA is the Federal agency in charge of contracting for advanced development of drugs to treat radiological, biological and chemical threats for the civilian population. BARDA also manages the $2.8BB Special Reserve Fund for the purchase of these drugs for the U.S. Strategic National Stockpile.